> Optimise the efficacy of current pre-erythrocytic vaccines while evaluating the safety and immunogenicity of new blood-stage mRNA vaccine candidates.

​

> Develop the next generation of highly efficacious malaria vaccine candidates using an advanced in-silico platform to analyse TCR- and single-cell sequencing data in combination with artificial intelligence (AI) based predictions of novel malaria vaccine antigens.

​

> Establish a European facility for the production of malaria sporozoites for research and clinical use.